Chinese biotech CStone on course to launch lung cancer drug after successful clinical trial
- Hong Kong-listed CStone Pharmaceuticals’ Sugemalimab treatment could become the first drug of its kind in China to be to approved for non-small cell lung cancer
- The market for the category of drug being developed by CStone is estimated at 40 billion yuan a year currently and is expected to touch 80 billion yuan in 10 years’ time
Corrected [7:19pm, 24 Aug, 2020]
- [7:19pm, 24 Aug, 2020]
This story was changed to show that the market for anti PD-1 or PD-L1 drugs is very large, and not just for PD-L1 drugs. It was also changed to show that Merck’s Keytruda was the first anti PD-1 therapy approved in combination with chemotherapy as a first line lung cancer treatment, with the emphasis on its nature as a first line treatment.